View PDF Version - RePub - Erasmus Universiteit Rotterdam

More documents

Recommendations

Info

Bibliography 258 Mechanical factors infl uencing the incidence of burst abdomen. Eur. J. Surg. 1995, 161:655- 661. 13. Helbing WA, Rebergen SA, Maliepaard C, Hansen B, Ottenkamp J, Reiber JHC, de Roos A. Quantifi cation of right ventricular function with magnetic resonance imaging in children with normal hearts and with congenital heart disease. Am Heart J. 1995, 130:828-837. 14. Reijnierse M, Bloem JL, Dijkmans BAC, Kroon HM, Holscher HC, Hansen B, Breedveld FC. The cervical spine in rheumatoid arthritis: relationship between neurologic signs and morphology on MR imaging and radiographs. Skeletal Radiol. 1996; 25: 113-118. 15. de Waard-Siebinga I, Hilders CGJM, Hansen BE, v Delft JL, Jager MJ. HLA expression and tumor-infi ltrating immune cells in uveal melanoma. Graefe’s Arch Clin Exp Ophthalmol. 1996;234:34-42. 16. Hagen EC, Andrassy K, Csernok E, Daha MR, Gaskin G, Gross WL, Hansen B, v.d. Woude FJ et al. Development and standardization of solid phase assays for the detection of antineutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. Journal of Immunological Methods 1996, 196 1-15. 17. Bajema I, Hagen EC, Hansen BE, Hermans J, Noël LH, Waldherr R, Ferrario F, v.d. Woude FJ, Bruijn JA. The renal histopathology in systemic vasculitis: an international survey study of inter- and intra-observer agreement. Nephrol Dial Transplant 1996, 11: 1989-1995. 18. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavalletto L, Schvarcz R, Ideo G, Alberti A. Ribavirin enhances the effi cacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J. Hepatl 1997; 26: 961-6. 19. Brouwer JT, Nevens F, Kleter B, Elewaut A, Adler M, Brenard R, Chamuleau RA, Michielsen PP, Pirotte J, Hautekeete ML, Weber J, Bourgeois N, Hansen BE, Bronkhorst CM, ten Kate FJ, Heijtink RA,Fevery J, Schalm SW. Effi cacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients.. Journal of Hepatology. 28(6):951-9, 1998 Jun. 20. Kuijpens JL, Hansen B, Hamming JF, Ribot JG, Haak HR, Coebergh J-WW. Trends in treatment and long-term survival of thyroid cancer in Southeastern Netherlands, 1960-1992. European Journal of Cancer. 34(8): 1235-1241, 1998 21. Referaat: Hansen B, de Man RA. Het effect van interferon alfa op het ontstaan van hepatocellulair carcinoom bij patienten met virale hepatitis en cirrose. Ned Tijdschr Geneeskd 1998 28 nov; 142(48) 22. van Hoogstraten HJ, Hansen BE, van Buuren HR, ten Kate FJ, van Berge-Henegouwen GP, Schalm SW. Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group. J Hepatol. 1999 Aug;31(2):256-62. 23. Schalm SW, Weiland O, Hansen BE, Milella M, Lai MY, Hollander A, Michielsen PP, Bellobuono A, Chemello L, Pastore G, Chen DS, Brouwer JT.
Bibliography 259 Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. Gastroenterology. 1999 Aug;117(2):408-13. 24. Brouwer JT, Hansen BE, Niesters HG, Schalm SW. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol. 1999 Feb;30(2):192-8. 25. van Overhagen H. Ludviksson MA. Lameris JS. Zwamborn AW. Tilanus HW. Dees J. Hansen BE. US and fl uoroscopic-guided percutaneous jejunostomy: Experience in 49 patients. Journal of Vascular & Interventional Radiology. 11(1):101-106, 2000 Jan. 26. Post PN. Hendrikx AJM. Hansen BE. van der Heijden LH. Coebergh JWV. Long-term survival of prostate cancer in southeastern Netherlands. Acta Oncologica. 39(1):101-104, 2000. 27. Reijnierse M. Breedveld FC. Kroon HM. Hansen B. Pope TL. Bloem JL. Are magnetic resonance fl exion views useful in evaluating the cervical spine of patients with rheumatoid arthritis?. Skeletal Radiology. 29(2):85-89, 2000 Feb. 28. Bekkering FC, Brouwer JT, Hansen BE, Schalm SW. Hepatitis C viral kinetics in diffi cult to treat patients receiving high dose interferon and ribavirin. J Hepatol. 2001 Mar;34(3):435-40. 29. Janssen HL, Wijnhoud A, Haagsma EB, van Uum SH, van Nieuwkerk CM, Adang RP,Chamuleau RA, van Hattum J, Vleggaar FP, Hansen BE, Rosendaal FR, van Hoek B. Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut. 2001 Nov;49(5):720-4. 30. Post PN, Hansen BE, Kil PJ, Janssen-Heijnen ML, Coebergh JW. The independent prognostic value of comorbidity among men aged < 75 years with localized prostate cancer: a population-based study. BJU Int. 2001 Jun;87(9):821-6. 31. Wolters LM, Hansen BE, Niesters HG, DeHertogh D, de Man RA. Corrigendum to “Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B” J Hepatol. 2002 Nov;37(5):708. 32. Wolters LM, Hansen BE, Niesters HG, de Man RA. Viral dynamics in chronic hepatitis B patients treated with lamivudine,lamivudine-famciclovir or lamivudine-ganciclovir. Eur J Gastroenterol Hepatol. 2002 Sep;14(9):1007-11. 33. Wolters LM, Hansen BE, Niesters HG, Levi-Drummer RS, Neumann AU, Schalm SW, de Man RA. The infl uence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine. J Hepatol. 2002 Aug;37(2):253-8. 34. Wolters LM, Hansen BE, Niesters HG, DeHertogh D, de Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol. 2002 Jul;37(1):137-44.
Page 1:
Statistical Models of Treatment Eff
Page 4 and 5:
ISBN: 978-90-8559-069-9 © Bettina
Page 6 and 7:
PROMOTIECOMMISSIE Promotor: Prof.dr
Page 9 and 10:
CONTENTS Chapter 1. Introduction 11
Page 13:
Cha pter 1 Introduction
Page 16 and 17:
Chapter 1 14 Epidemiology Worldwide
Page 18 and 19:
Chapter 1 16 Prediction models with
Page 20 and 21:
Chapter 1 18 standard method fails
Page 22 and 23:
Chapter 1 20 The extended non-linea
Page 24 and 25:
Chapter 1 22 References 1. Blumberg
Page 27:
Cha pter 2 Prediction of response t
Page 30 and 31:
Chapter 2.1 28 ABSTRACT The aim of
Page 32 and 33:
Chapter 2.1 30 been hepatitis B sur
Page 34 and 35:
Chapter 2.1 32 HBV DNA decline The
Page 36 and 37:
Chapter 2.1 34 Figure 2 continued.
Page 38 and 39:
Chapter 2.1 36 Figure 4. Estimated
Page 40 and 41:
Chapter 2.1 38 DNA was observed in
Page 42:
Chapter 2.1 40 15. Kao JH. Role of
Page 46 and 47:
Chapter 2.2 44 ABSTRACT Background:
Page 48 and 49:
Chapter 2.2 46 low baseline HBV DNA
Page 50 and 51:
Chapter 2.2 48 patient subgroups wa
Page 52 and 53:
Chapter 2.2 50 p=0.002). Previous I
Page 54 and 55:
Chapter 2.2 52 Application of the m
Page 56 and 57:
Chapter 2.2 54 PEG-IFN, the proport
Page 58 and 59:
Chapter 2.2 56 References 1. Lavanc
Page 60 and 61:
Chapter 2.2 58 26. Bonino F, Lau GK
Page 63 and 64:
Chap ter 2.3 Prediction of the resp
Page 65 and 66:
INTRODUCTION Dynamic prediction of
Page 67 and 68:
Statistical analysis Dynamic predic
Page 69 and 70:
Dynamic prediction of response to P
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
References Dynamic prediction of re
Page 81 and 82:
Cha pter 2.4 Dynamic prediction of
Page 83 and 84:
INTRODUCTION Dynamic prediction of
Page 85 and 86:
For the indirect approach we rewrit
Page 87 and 88:
logit pi,j = logit Pr(Ri =1|visit =
Page 89 and 90:
Dynamic prediction of response usin
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Table 1. Results of different stopp
Page 103 and 104:
Page 105:
Page 108 and 109:
Chapter 2.5 106 ABSTRACT Peginterfe
Page 110 and 111:
Chapter 2.5 108 and placebo daily.
Page 112 and 113:
Chapter 2.5 110 for patients with a
Page 114 and 115:
Chapter 2.5 112 Mean HBV DNA declin
Page 116 and 117:
Chapter 2.5 114 peginterferon and n
Page 118 and 119:
Chapter 2.5 116 hepatocellular carc
Page 120 and 121:
Chapter 2.5 118 13. Werle-Lapostoll
Page 122:
Chapter 2.5 120 Greece - G Germanid
Page 127 and 128:
Chap ter 3.1 Long-term clinical out
Page 129 and 130:
INTRODUCTION Glycyrrhizin for IFN-n
Page 131 and 132:
Statistics Glycyrrhizin for IFN-non
Page 133 and 134:
Glycyrrhizin for IFN-non responders
Page 135 and 136:
Table 2. Time dependent Cox regress
Page 137 and 138:
Page 139 and 140:
Page 143 and 144:
Cha pter 3.2 Discriminant analysis
Page 145 and 146:
Introduction Discriminant analysis
Page 147 and 148:
Discriminant analysis using a MLMM
Page 149 and 150:
Estimation Discriminant analysis us
Page 151 and 152:
Page 153 and 154:
where wi,k(y i, θ) = (k =1,...,K).
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Appendix Discriminant analysis usin
Page 175:
Cha pter 4 Statistical models of ea
Page 178 and 179:
Chapter 4.1 176 ABSTRACT Nucleoside
Page 180 and 181:
Chapter 4.1 178 at day 1 at t =0 an
Page 182 and 183:
Chapter 4.1 180 Table 1. Baseline c
Page 184 and 185:
Chapter 4.1 182 Figure 1.
Page 186 and 187:
Chapter 4.1 184 Figure 1. Viral dec
Page 188 and 189:
Chapter 4.1 186 suppression in seru
Page 190 and 191:
Chapter 4.1 188 13. Seifer M, Hamat
Page 193 and 194:
Cha pter 4.2 Viral dynamics during
Page 195 and 196:
INTRODUCTION Viral dynamics during
Page 197 and 198:
Viral dynamics during tenofovir the
Page 199 and 200:
Page 201 and 202:
log HBV DNA (copies/mL) 10.0 9.0 8.
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 211 and 212: Chap ter 4.3 Modelling of early vir
Page 213 and 214: INTRODUCTION HBV viral kinetics dur
Page 215 and 216: HBV viral kinetics during PEG-IFN 2
Page 229: HBV viral kinetics during PEG-IFN 2
Page 233 and 234: SUMMARY AND CONCLUSION Summary and
Page 235 and 236: Summary and conclusion 233 The mode
Page 237 and 238: Summary and conclusion 235 The infe
Page 239: Summary and conclusion 237 Early st
Page 243 and 244: SAMENVATTING EN CONCLUSIE Samenvatt
Page 245 and 246: Samenvatting en conclusie 243 Er we
Page 247 and 248: Samenvatting en conclusie 245 Data
Page 249 and 250: Samenvatting en conclusie 247 Behan
Page 253: Dan kwoord
Page 256 and 257: Dankwoord 254 Lieve Marion en Margr
Page 259: BIBLI OGRAPHY Bibliography 257 1. K
Page 263 and 264: Bibliography 261 Long term clinical
Page 265 and 266: Bibliography 263 Flares in chronic
Page 267 and 268: Bibliography 265 Genetic characteri
Page 269: Bibliography 267 106. Reijnders JG,
show all

View PDF Version - RePub - Erasmus Universiteit Rotterdam

Create successful ePaper yourself

Delete template?

Save as template?